Top 10 Books about Stock Investing to read in 2018. Read more.

ECYT - Endocyte

Industry: Biotechnology Sector: Healthcare Exchange: NASDAQ

Fri 20'th Apr 2018

PERIOD 2018-01-22 - 2018-04-20
CHANGE -2.18%
PRICE $9.41
VOLUME
Buy
TREND
Buy

MV LONG
Buy

MV SHORT
Sell

PIVOT
Sell

MACD
Buy

Request Prediction
0.00%
Predict

Endocyte Stock Analysis

Technical stock analysis for Fri 20'th Apr 2018

Buy candidate since 2018-03-02 Gain 44.77%

Endocyte fell by -2.18% in the last day from $9.62 to $9.41 and has now fallen 4 days in a row. The price has fallen in 6 of the last 10 days , but is still up by 13.37% over the past 2 weeks. Volume has increased in the last day by 51 168 shares, but on falling prices. This may be an early warning and the risk will be increased slightly for the next couple of days. In total, 650 382 shares bought and sold for approximately $6.12 million.

Shorts 0.70% ( 2018-03-29 )
Cash 349.0 mill
Loans n/a
Beta 0.49
ROA -41.64

Trend

Endocyte lies in the lower part of a very wide and strong rising trend in the short term, and this will normally pose a very good buying opportunity. A break down the bottom trend line at $8.68 will firstly indicate a slower raising rate, but may also be a early warning for a trend shift. Given the current short-term trend, the stock is expected to rise 142.3% during the next 3 months and, with 90% probability hold a price between $21.03 and $35.23 at the end of this period.

Click here for today's Top 5 Trending Companies

Signals

There are mixed signals in the stock today. A sales signal was issued from a pivot top point on Tuesday April 17, 2018, which indicates further falls until a new bottom pivot has been found. Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely. Endocyte holds a sales signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock. On further gains, the stock will meet resistance from the short-term moving average at approximately $9.59. On a fall, the stock will find some support from the long-term average at approximately $9.06. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sales signal.

Access today's Top 5 Golden Star Companies

Relative Strength Index (RSI)

RSI14 is 63 and the stock is currently not being overbought or oversold

Access full RSI 14 and RSI 21 lists

Support & Resistance

On the downside, the stock finds support just below today's level from accumulated volume at $8.83 and $8.20. On the upside the stock meets some resistance from accumulated volume at $10.34, $10.38 and $10.82.

There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Endocyte finds support just below today's level at $8.83. If this is broken, then the next support from accumulated volume will be at $8.20 and $8.06.

Support: $8.83 Price: $9.41 Resistance: $10.34

Risk

This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.48 between high and low, or 5.19%. For the last week, the stock has had a daily average volatility of 7.08%.

Our recommended stoploss: $8.77 (-6.78%) (This stock has medium daily movements and this gives medium risk. There is a sell signal from pivot top found 3 days ago.)

Overall risk:

Very Low Low Medium High Very High

Evaluation

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for this stock to perform well in the short-term.

Trade ECYT CFDs with Plus500

Your capital is at risk.

Important: Plus500 doesn't offer signals and it is a CFD service.
Plus500UK Ltd is authorised and regulated by the Financial Conduct Authority (FRN 509909).

Access these features

Auto portfolios gaining up to 30%
Top 5 Candidates in all Lists
Ultimate List Builder
Ad-free browsing

Become a PRO Now
Help us IMPROVE our CHARTS HERE.

Last donation

Do you find our website useful too?
Help us improve by making a small donation or
Get PRO features

START FREE 5-DAY TRIAL